We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors—A Single-Center Study.
- Authors
Amylidi, Anna Lea; Gogadis, Aristeidis; Yerolatsite, Melina; Zarkavelis, George; Torounidou, Nanteznta; Keramisanou, Varvara; Kampletsas, Eleftherios; Mauri, Davide
- Abstract
Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 inhibitors, have become the standard of care for many cancer types. However, they induce immune-related adverse events (irAEs), including neurotoxicity and hypophysitis. The incidence and outcomes of neurotoxicity and hypophysitis in patients treated with immune checkpoint inhibitors are not well established. We conducted a retrospective study of 812 patients with solid cancers who received immune checkpoint inhibitors at the University General Hospital of Ioannina between January 2018 and January 2023. We assessed demographic and clinical data, including the severity of symptoms, treatment regimen, other irAEs, resolution type and time, and death. Two patients experienced neurotoxicity and two hypophysitis. All four patients required inpatient administration and received corticosteroids or/and hormone replacement. Three patients responded to the initial therapy, experiencing full recovery, while one patient was corticosteroid-resistant, and immunoglobin G was administered. Two patients never received immunotherapy after their toxicity due to the severity of symptoms; one patient continued monotherapy with nivolumab, changing from combination therapy with ipilimumab–nivolumab, while the fourth patient continued his initial treatment with nivolumab. Our study suggests that the incidence of neurotoxicity and hypophysitis in patients treated with immune checkpoint inhibitors is low, but careful monitoring and prompt treatment with corticosteroids are necessary for effective management.
- Subjects
IOANNINA (Greece); IMMUNE checkpoint inhibitors; DRUG side effects; THERAPEUTICS; CANCER patients; CANCER complications
- Publication
Current Oncology, 2023, Vol 30, Issue 12, p10509
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol30120766